KROSNasdaqPharmaceutical PreparationsFiscal year ends December 31
Keros Therapeutics, Inc.
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 3, 2026
$11.06+0.40 (+3.75%)
Close on Oct 19, 2026
- Market cap
- $218.99M
- P/E (TTM)
- –
- Dividend yield
- –
Keros Therapeutics, Inc. revenue by segment
By business segment
By product or service
| Revenue | Q2 26 | Q1 26 | Q4 25 | Q3 25 | Q2 25 | Q1 25 | Q4 24 | Q3 24 | Q2 24 | Q1 24 | Q4 23 | Q3 23 | % of revenue | YoY |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Service and other revenue | $0 | $367.00K | $385.00K | $4.26M | $18.17M | $15.89M | $42.00K | $388.00K | $37.00K | $83.00K | $143.00K | $8.00K | – | -100.0% |
| License revenue | $0 | $0 | $0 | $10.00M | $0 | $195.36M | $3.00M | $0 | $0 | $0 | – | – | – | – |
| Service revenue | $0 | $32.00K | $371.00K | $4.12M | $18.17M | $15.84M | $0 | $0 | $0 | $0 | – | – | – | -100.0% |
| License revenue | $0 | $0 | $0 | $10.00M | $0 | $195.36M | $0 | $0 | $0 | $0 | – | – | – | – |
By region
From the segment and revenue-disaggregation notes of Keros Therapeutics's 10-K and 10-Q filings (XBRL). Fourth-quarter figures are the fiscal year less the first nine months. Segment names follow the company's own labels and can change when it reorganizes.